Research

Excellence in clinical care stems from advances in understanding the fundamental basis for abnormalities of the nervous system and the resulting development of new and more effective treatment strategies for nervous system disorders. For this reason, research remains an integral part of the Department of Neurology. Members of the faculty in Neurology have a broad range of research interests that span the areas of molecular biology, electrophysiology, biophysics, pharmacology, molecular genetics, immunopathology, neurotransplantation and computational neuroscience as pertaining to nervous system disorders.

The Department is highly committed to translation of basic research findings to the clinical domain and actively promotes productive interactions between clinicians and basic scientists, and provides resources for collaborative translational studies. Members of the faculty include world-renowned leaders in their fields of research who continue significantly to enhance the understanding of the nervous system and its disorders.

Centers and Programs

The Department also includes a selection of research centers and programs:

  • Alzheimer's Disease Research Center: The goal of the ADRC is to advance the understanding and treatment of Alzheimer's Disease through research, clinical trials, and career development for Alzheimer researchers, community outreach and education.
  • Cellular Neuroscience, Neurodegeneration and Repair: The interdepartmental program in Cellular Neuroscience, Neurodegeneration and Repair (CNNR) will accelerate the pace of Yale’s research on neurodegenerative diseases and nerve injury and repair.
  • Center for Neuroscience and Regeneration Research: The CNRR is a model of inter-institutional cooperation that brings together the strengths of the Paralyzed Veterans of America, United Spinal Association, Department of Veterans Affairs, and Yale University School of Medicine in a collaborative effort, toward the development of effective treatments, and ultimately a cure, for spinal cord injury, multiple sclerosis and related disorders such as neuropathic pain syndromes, ischemic stroke and TBI.
  • Center for Neuroepidemiology and Clinical Neurological Research: The Center for Neuroepidemiology and Clinical Neurological Research is a 'virtual center' comprised of researchers across departments and schools at Yale with common interests.
  • Clinical Neurosciences Imaging Center: The Yale Clinical Neuroscience Imaging Center (CNIC) provides an integrated core for collaborative research on disorders of the nervous system.
  • Program in Clinical & Translational Neuromuscular Research: This translational research program is focused on bridging the gap between clinical care and the basic sciences in neuromuscular disorders. 
  • Yale Center for Experimental Neuroimaging: The mission of YCEN is to foster interactions between Yale investigators who use advanced microscopy and in vivo imaging tools to study the physiology and pathology of the central and peripheral nervous systems.

Networks

The Department also participates in national neurology research networks:

NeuroNEXT:

INFINITY (Investigations For Improved Neurological Treatments at Yale) was selected in 2018 by the National Institutes of Neurological Disorders and Stroke (NINDS) as one of approximately 25 U.S. sites designated to participate in the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT). This network conducts both biomarker validation and Phase 2 studies of treatment for neurological disease in adults and children through partnerships with academia, private foundations and industry. NeuroNEXT is designed to expand NINDS's capabilty to test the most promising new therapies; increase the efficiency of clinical trials before on embarking on larger studies; and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. INFINITY is a highly effective research team which includes both adult and pediatric neurologists, neurosurgeons, neuropsychologists, neuroradiologists, and translational scientists committed to conducting high impact clinical trials in neurological diseases. 

StrokeNet:

SPIRIT (Southern New England Partnership In Stroke Research, Innovation and Treatment) was selected in 2018 by the National Institutes of Health (NIH) as one of approximately 25 U.S. Sites designed to participate in StrokeNet. The primary goal of this network is to maximize efficiencies to develop, promote and conduct high-quality, multi-site clinical trials focused on key interventions in stroke prevention, treatment and recovery. The StrokeNet Network is designed to serve as the infrastructure and pipeline for exciting new potential treatments for patients with stroke and those at risk for stroke. SPIRIT is anchored by 3 leading institutes: Yale School of Medicine, Warren Alpert School of Medicine at Brown University, and Hartford Hospital